Effectiveness of pertussis vaccination and duration of immunity
- PMID: 27672225
- PMCID: PMC5088088
- DOI: 10.1503/cmaj.160193
Effectiveness of pertussis vaccination and duration of immunity
Abstract
Background: A resurgence of pertussis cases among both vaccinated and unvaccinated people raises questions about vaccine effectiveness over time. Our objective was to study the effectiveness of the pertussis vaccine and characterize the effect of waning immunity and whole-cell vaccine priming.
Methods: We used the test-negative design, a nested case-control study with test-negative individuals as controls. We constructed multivariable logistic regression models to estimate odds ratios (ORs). Vaccine effectiveness was calculated as (1 - OR) × 100. We assessed waning immunity by calculating the odds of developing pertussis per year since last vaccination and evaluated the relative effectiveness of priming with acellular versus whole-cell vaccine.
Results: Between Dec. 7, 2009, and Mar. 31, 2013, data on 5867 individuals (486 test-positive cases and 5381 test-negative controls) were available for analysis. Adjusted vaccine effectiveness was 80% (95% confidence interval [CI] 71% to 86%) at 15-364 days, 84% (95% CI 77% to 89%) at 1-3 years, 62% (95% CI 42% to 75%) at 4-7 years and 41% (95% CI 0% to 66%) at 8 or more years since last vaccination. We observed waning immunity with the acellular vaccine, with an adjusted OR for pertussis infection of 1.27 (95% CI 1.20 to 1.34) per year since last vaccination. Acellular, versus whole-cell, vaccine priming was associated with an increased odds of pertussis (adjusted OR 2.15, 95% CI 1.30 to 3.57).
Interpretation: We observed high early effectiveness of the pertussis vaccine that rapidly declined as time since last vaccination surpassed 4 years, particularly with acellular vaccine priming. Considering whole-cell vaccine priming and/or boosters in pregnancy to optimize pertussis control may be prudent.
© 2016 Canadian Medical Association or its licensors.
Figures

Similar articles
-
Acellular pertussis vaccine effectiveness and waning immunity in Alberta, Canada: 2010-2015, a Canadian Immunization Research Network (CIRN) study.Vaccine. 2019 Jul 9;37(30):4140-4146. doi: 10.1016/j.vaccine.2019.05.067. Epub 2019 Jun 1. Vaccine. 2019. PMID: 31164304
-
Pertussis vaccine effectiveness in a frequency matched population-based case-control Canadian Immunization Research Network study in Ontario, Canada 2009-2015.Vaccine. 2019 May 1;37(19):2617-2623. doi: 10.1016/j.vaccine.2019.02.047. Epub 2019 Apr 6. Vaccine. 2019. PMID: 30967309
-
Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.JAMA. 2012 Nov 28;308(20):2126-32. doi: 10.1001/jama.2012.14939. JAMA. 2012. PMID: 23188029
-
Pertussis in the Era of New Strains of Bordetella pertussis.Infect Dis Clin North Am. 2015 Dec;29(4):699-713. doi: 10.1016/j.idc.2015.07.005. Epub 2015 Sep 1. Infect Dis Clin North Am. 2015. PMID: 26337739 Review.
-
Controlling pertussis: how can we do it? A focus on immunization.Expert Rev Vaccines. 2018 Apr;17(4):289-297. doi: 10.1080/14760584.2018.1445530. Epub 2018 Mar 12. Expert Rev Vaccines. 2018. PMID: 29482390 Review.
Cited by
-
Under-reporting of pertussis in Ontario: A Canadian Immunization Research Network (CIRN) study using capture-recapture.PLoS One. 2018 May 2;13(5):e0195984. doi: 10.1371/journal.pone.0195984. eCollection 2018. PLoS One. 2018. PMID: 29718945 Free PMC article.
-
Letter to the editor: Is the acellular pertussis vaccine driving the increase in severe whooping cough cases in children?Euro Surveill. 2024 Sep;29(37):2400574. doi: 10.2807/1560-7917.ES.2024.29.37.2400574. Euro Surveill. 2024. PMID: 39268650 Free PMC article. No abstract available.
-
Validating pertussis data measures using electronic medical record data in Ontario, Canada 1986-2016.Vaccine X. 2023 Nov 21;15:100408. doi: 10.1016/j.jvacx.2023.100408. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38161988 Free PMC article.
-
Seroprevalence of Bordetella pertussis toxin antibodies in children and adolescents in Tunis, Tunisia.Epidemiol Infect. 2019 Jan;147:e199. doi: 10.1017/S0950268819000840. Epidemiol Infect. 2019. PMID: 31364527 Free PMC article.
-
The Decay of Pertussis Antibodies in Children Aged 0-14 Years in Jiangsu Province, China.Vaccines (Basel). 2023 Aug 7;11(8):1336. doi: 10.3390/vaccines11081336. Vaccines (Basel). 2023. PMID: 37631904 Free PMC article.
References
-
- Pertussis (whooping cough): for health care professionals. Ottawa: Health Canada; modified 2014. Available: www.phac-aspc.gc.ca/im/vpd-mev/pertussis/professionals-professionnels-en... (accessed 2014 May 29).
-
- Bentsi-Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997;15:301–6. - PubMed
-
- De Serres G, Boulianne N, Duval B, et al. Effectiveness of a whole cell pertussis vaccine in child-care centers and schools. Pediatr Infect Dis J 1996;15:519–24. - PubMed
-
- Halperin SA, Bortolussi R, MacLean D, et al. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 1989; 115:686–93. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials